
Viridian Therapeutics (VRDN) Stock Forecast & Price Target
Viridian Therapeutics (VRDN) Analyst Ratings
Bulls say
Viridian Therapeutics is positioned for success with the FDA approval and successful launch of Lumvoa, a best-in-class treatment for TED, and upcoming catalysts, showcasing its strong pipeline and potential for growth. With a new at-home treatment in development and a strong focus on rare diseases, VRDN has potential to capture a significant portion of the market and generate significant revenue in the near future. Its competitive edge and innovative approach make it a favorable investment option for those looking to invest in the healthcare sector.
Bears say
Viridian Therapeutics is facing several challenges, including minimal revenue in the short term due to payer coverage dynamics, competition from larger companies such as AMGN's Tepezza, and the need for additional capital to complete their pipeline and establish commercial manufacturing capabilities. While the company's early commercial launch metrics for Lumvoa and positive results from their clinical trials are encouraging, it remains to be seen how they will compete in the already crowded TED market. Without significant market share or revenue, the company's future success and financial stability may be uncertain.
This aggregate rating is based on analysts' research of Viridian Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viridian Therapeutics (VRDN) Analyst Forecast & Price Prediction
Start investing in Viridian Therapeutics (VRDN)
Order type
Buy in
Order amount
Est. shares
0 shares